NCT05849480 2026-02-05A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)National Institutes of Health Clinical Center (CC)Phase 1/2 Recruiting60 enrolled